NEW GENRE Volume One: The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures

Capítulo 2, 3.1, 3.2, 3.3, 3.4, 4.2, 5.1.1, 5.1.2, 5.2.1, 5.2.2, 5.2.3, 5.3.2, 5.5.1 – 5.5.7, 5.5.9, 5.5.10, 5.6.1, 5.6.4, 5.6.5, 6.1, 6.2, 6.3 – 6.6, 7.2

Gail S Thornton, MA, PhD(c)

2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 5.4.3, 5.6.6, 5.7.1, 8.2

Aviva Lev-Ari, PhD, RN

Prefacio, 1.1, 4.1, 5.1.2, 5.5.8, 6.1, 6.2

Stephen J. Williams, PhD

1.2, 1.3, 5.4.1, 5.4.2

Demet Sag, PhD

1.4

Ritu Saxena, PhD

5.6.2

Tilda Barliya, PhD

5.6.3

Sudipta Saha, PhD

7.1

AUTORES INVITADOS

Autor invitado: Ferez Nallaseth, PhD

8.1

Autor invitado: Itzhak Brook MD, MSc, Departamento de Pediatría, Facultad de Medicina de la Universidad de Georgetown, Washington DC

1.5

Autor invitado: Clifford Thornton

8.3

Los enlaces indicados llevan al contenido original en inglés

MD	Licenciado/a en medicina y cirugía (Estados Unidos)
PhD	Doctorado/a
RN	Enfermero/a titulado/a (National Board of Nursing Registration)
FCAP	Miembro distinguido (Fellow) del Colegio de Anatomopatólogos de los Estados Unidos
M.A.	M.A.

Indice de contenidos electrónico (IDCe)

Prefacio por Aviva Lev-Ari, PhD, RN

Introducción del volumen por Larry H. Bernstein, MD, FCAP

Primera parte:

Percepción de la atención sanitaria

Introducción

Larry H. Bernstein, MD, FCAP

Capítulo 1: Impresiones personales

1.1 La historia personal de JL y la secuenciación de su genoma completo

https://pharmaceuticalintelligence.com/2012/11/24/personal-tale-of-jls-whole-genome-sequencing/

Reportero: Aviva Lev-Ari, PhD, RN

1.2 Notas en directo de la reunión #cbi16 de AACR sobre medicina de precisión: 5:10 p.m. Gran idea, la historia de una superviviente

https://pharmaceuticalintelligence.com/2016/02/17/live-notes-from-aacrs-cbi16-meeting-on-precision-medicine-510pm-big-idea-a-survivors-story/

Reportero: Stephen J. Williams, Ph.D.

1.3 Notas en directo de la reunión #cbi16 de AACR sobre medicina de precisión: historia de éxito y el Dr. Stephan Grupp

https://pharmaceuticalintelligence.com/2016/01/21/live-notes-from-aacrs-cbi16-meeting-on-precision-medicine-success-story-and-dr-stephen-grupp/

Reportero: Stephen J. Williams, Ph.D.

1.4 Tratamientos paliativos: mantener la mente fuerte durante el cáncer

https://pharmaceuticalintelligence.com/2015/11/03/supportive-treatments-hold-the-mind-strong-during-cancer/

Autor: Demet Sag, PhD

1.5 Encontrar mi voz: la historia de un laringectomizado

https://pharmaceuticalintelligence.com/2016/05/08/finding-my-voice-a-laryngectomee-laryngectomy-story/

Autor invitado: Itzhak Brook MD, MSc, Departamento de Pediatría, Facultad de Medicina de la Universidad de Georgetown, Washington DC

Capítulo 2: Artículos sobre la percepción de la atención sanitaria

Introducción

Larry H. Bernstein, MD, FCAP

2.1 La prestación de atención sanitaria. Fuentes externas. Se dejan intencionadamente como referencias en los enlaces.

Track, trigger and teamwork: Communication of deterioration in acute medical and surgical wards Article

Intensive and Critical Care Nursing, Volume 26, Issue 1, Pages 10-17

Donohue, L.A.; Endacott, R.

Cited by Scopus (19)

Communication interaction in ICU-Patient and staff experiences and perceptions Article

Intensive and Critical Care Nursing, Volume 22, Issue 3, Pages 167-180

Magnus, V.S.; Turkington, L.

Cited by Scopus (39)

Nursing care in a high-technological environment: Experiences of critical care nurses Article

Intensive and Critical Care Nursing, Volume 31, Issue 2, Pages 116-123

Tunlind, A.; Granstrom, J.; Engstrom, A.

Knowledge, attitudes and barriers towards prevention of pressure ulcers in intensive care units: A descriptive cross-sectional study Article

Intensive and Critical Care Nursing, Volume 26, Issue 6, Pages 335-342

Strand, T.; Lindgren, M.

Rehabilitation during mechanical ventilation: Review of the recent literature Review article

Intensive and Critical Care Nursing, Volume 31, Issue 3, Pages 125-132

Ntoumenopoulos, G.

Reducing risk for ventilator associated pneumonia through nursing sensitive interventions Article

Intensive and Critical Care Nursing, Volume 29, Issue 5, Pages 261-265

Micik, S.; Besic, N.; Johnson, N.; Han, M.; Hamlyn, S.; Ball, H.

The lived experiences of adult intensive care patients who were conscious during mechanical ventilation: A phenomenological-hermeneutic study Article

Intensive and Critical Care Nursing, Volume 28, Issue 1, Pages 6-15

Karlsson, V.; Bergbom, I.; Forsberg, A.

Families’experiences of their interactions with staff in an Australian intensive care unit (ICU): A qualitative study Article

Intensive and Critical Care Nursing, Volume 31, Issue 1, Pages 51-63

Wong, P.; Liamputtong, P.; Koch, S.; Rawson, H.

Experiences of critically ill patients in the ICU Article

Intensive and Critical Care Nursing, Volume 24, Issue 5, Pages 300-313

Hofhuis, J.G.M.; Spronk, P.E.; van Stel, H.F.; Schrijvers, A.J.P.; Rommes, J.H.; Bakker, J.

Cited by Scopus (54)

2.2 Director general de un hospital. Un nuevo estándar en la atención sanitaria: el Hospital Farrer Park, el primer complejo sanitario y hotelero totalmente integrado de Singapur

https://pharmaceuticalintelligence.com/2016/06/22/a-new-standard-in-health-care-farrer-park-hospital-singapores-first-fully-integrated-healthcarehospitality-complex/

Autor: Gail S. Thornton, M.A.

2.3 Descubrimiento de fármacos para la cura del cáncer: valor para los pacientes. Aplicación de los avances científicos: estudio de caso de una empresa farmacéutica líder mundial, Astellas Pharma Inc.

https://pharmaceuticalintelligence.com/2016/08/24/value-for-patients-turning-advances-in-science-a-case-study-of-a-leading-global-pharmaceutical-company-astellas-pharma-inc/

Autor: Gail S. Thornton, M.A.

2.4 Director general de un hospital. Una rica tradición de atención centrada en el paciente: el Centro Médico de la Universidad de Richmond, líder en atención sanitaria y formación médica de Nueva York

https://pharmaceuticalintelligence.com/2016/10/17/a-rich-tradition-of-patient-focused-care-richmond-university-medical-center-new-yorks-leader-in-health-care-and-medical-education/

Autor: Gail S. Thornton, M.A.

2.5 Director general de un hospital. Hospital Infantil Universitario de Zúrich (Universitäts-Kinderspital Zürich), Suiza: un destacado centro de investigación y medicina pediátrica

https://pharmaceuticalintelligence.com/2016/12/21/university-childrens-hospital-zurich-universitats-kinderspital-zurich-switzerland-a-prominent-center-of-pediatric-research-and-medicine/

Autor: Gail S. Thornton, M.A.

2.6 Director general de un hospital. Centro Suizo de Parapléjicos, Nottwil, Suiza: una clínica referente mundial para las lesiones medulares

https://pharmaceuticalintelligence.com/2017/03/23/swiss-paraplegic-centre-nottwil-switzerland-a-world-class-clinic-for-spinal-cord-injuries/

Autor: Gail S. Thornton, M.A.

2.7 Director de un instituto de investigación: el Instituto de Salud Global de Rutgers, parte de la facultad de Ciencias Biomédicas y de la Salud de la Universidad de Rutgers, New Brunswick, Nueva Jersey. Una nueva empresa diseñada para mejorar la salud y el bienestar a nivel mundial

https://pharmaceuticalintelligence.com/2017/04/17/the-rutgers-global-health-institute-part-of-rutgers-biomedical-and-health-sciences-rutgers-university-new-brunswick-new-jersey-a-new-venture-designed-to-improve-health-and-wellness-globa/

Autor: Gail S. Thornton, M.A.

2.8 Rector y director científico de un centro: City of Hope, Duarte, California. Combinando la ciencia con el alma para obrar milagros en un centro oncológico integral designado por el Instituto Nacional del Cáncer. Una entrevista con el rector y director científico de City of Hope, Steven T. Rosen, M.D.

https://pharmaceuticalintelligence.com/2017/05/11/city-of-hope-duarte-california-combining-science-with-soul-to-create-miracles-at-a-comprehensive-cancer-center-designated-by-the-national-cancer-institute-an-interview-with-the-p/

Autor: Gail S. Thornton, M.A.

2.9 El futuro de los hospitales: cómo colaboran la asistencia médica y la tecnología para mejorar la atención al paciente

https://pharmaceuticalintelligence.com/2017/05/31/the-future-of-hospitals-how-medical-care-and-technology-work-together-to-advance-patient-care/

Autor: Gail S. Thornton, M.A.

Resumen

Larry H. Bernstein, MD, FCAP

Segunda parte:

La voz de los supervivientes del cáncer

Capítulo 3: Un diagnóstico llamado «CÁNCER»

Introducción

Larry H. Bernstein, MD, FCAP

3.1 Diagnóstico complementario del cáncer

https://pharmaceuticalintelligence.com/2015/11/14/cancer-companion-diagnostics/

Redactor: Larry H. Bernstein, MD, FCAP

3.2 Los ARN largos no codificantes en los cánceres humanos

https://pharmaceuticalintelligence.com/2015/10/13/lncrnas-in-human-cancers/

Redactor: Larry H. Bernstein, MD, FCAP

3.3 Un ensayo de biopsia líquida podría predecir la resistencia a los fármacos

https://pharmaceuticalintelligence.com/2015/11/06/liquid-biopsy-assay-may-predict-drug-resistance/

Redactor: Larry H. Bernstein, MD, FCAP

3.4 Biomarcadores farmacogenómicos para el tratamiento personalizado del cáncer

https://pharmaceuticalintelligence.com/2015/10/09/pharmacogenomic-biomarkers-for-personalized-cancer-treatment-3-7/

Redactor: Larry H. Bernstein, MD, FCAP

Capítulo 4: Experiencia de los pacientes con la cirugía invasiva y la cirugía mínimamente invasiva

4.1 Medicina personalizada: biología celular del cáncer y cirugía mínimamente invasiva (CMI)

https://pharmaceuticalintelligence.com/2012/12/01/personalized-medicine-cancer-cell-biology-and-minimally-invasive-surgery-mis/

Redactor: Aviva Lev-Ari, PhD, RN

4.2 Cardiotoxicidad y miocardiopatía por efectos adversos de medicamentos

https://pharmaceuticalintelligence.com/2013/04/11/cardiotoxicity-and-cardiomyopathy-related-to-drugs-adverse-effects/

Redactor: Larry H. Bernstein, MD, FCAP

Capítulo 5: Tipos de cáncer y experiencia de los pacientes

5.1 Cáncer tiroideo

5.1.1 Experiencia con el cáncer de tiroides

https://pharmaceuticalintelligence.com/2015/11/23/my-experience-with-thyroid-cancer/

Redactor: Larry H. Bernstein, MD, FCAP

5.1.2 Vías de señalización del cáncer y progresión tumoral: imágenes de procesos biológicos explicadas por un patólogo experto en cáncer

https://pharmaceuticalintelligence.com/2015/06/09/cancer-signaling-pathways-and-tumor-progression-images-of-biological-processes-in-the-voice-of-a-pathologist-cancer-expert/

Autor y redactor de la ilustración: Larry H Bernstein, MD, FCAP y editor: Aviva Lev-Ari, PhD, RN

5.2 Cirugía cerebral

5.2.1 La experiencia de un primo con una acromegalia hipofisaria

https://pharmaceuticalintelligence.com/2015/11/23/my-cousins-experience-with-a-pituitary-acromegaly/

Autor: Larry H. Bernstein, MD, FCAP

5.2.2 Pérdida de la regulación normal del crecimiento

https://pharmaceuticalintelligence.com/2014/07/06/loss-of-normal-growth-regulation/

Redactor: Larry H. Bernstein, MD, FCAP

5.2.3 Glioma, glioblastoma y neurooncología

https://pharmaceuticalintelligence.com/2015/10/19/glioma-glioblastoma-and-neurooncology/

Redactor: Larry H. Bernstein, MD, FCAP

5.3 Cáncer de mama

5.3.1 Las caras del cáncer de mama. Encuentra tu historia y únete a la conversación

Por TARA PARKER-POPE

https://pharmaceuticalintelligence.com/2015/02/19/faces-of-breast-cancer/

5.3.2 Una decisión emocional y reflexiva sobre el BRCA1 y la cirugía

https://pharmaceuticalintelligence.com/2015/11/24/an-emotional-and-thoughtful-decision-over-brac1-and-surgery/

Redactor: Larry H. Bernstein, MD, FCAP

5.4 Cáncer de ovario

5.4.1 Una historia resumida de la ciencia que hay detrás del ensayo del β-bloqueante para el tratamiento del cáncer de ovario

https://pharmaceuticalintelligence.com/2015/10/26/a-curated-history-of-the-science-behind-the-ovarian-cancer-%CE%B2-blocker-trial/

Redactor: Stephen J. Williams, Ph.D.

5.4.2 Buenas y malas noticias sobre el tratamiento del cáncer de ovario

https://pharmaceuticalintelligence.com/2014/07/01/good-and-bad-news-reported-for-ovarian-cancer-therapy-2/

Reportero y editor: Stephen J. Williams, Ph.D.

5.4.3 La historia de Almudena: una vida de esperanza, rejuvenecimiento y fuerza

https://pharmaceuticalintelligence.com/2016/08/10/almudenas-story-a-life-of-hope-rejuvenation-and-strength/

Autor: Gail S. Thornton, M.A.

5.5 Neoplasias hematológicas malignas

5.5.1 Diagnóstico de las neoplasias hematológicas malignas

https://pharmaceuticalintelligence.com/2015/08/11/hematological-malignancy-diagnostics-4-2-3/

Autor y redactor: Larry H. Bernstein, MD, FCAP

5.5.2 Clasificación de los cánceres hematológicos

https://pharmaceuticalintelligence.com/2015/08/11/hematological-cancer-classification-2-4/

Autor y redactor: Larry H. Bernstein, MD, FCAP

5.5.3 Quimioterapia en la LMA

https://pharmaceuticalintelligence.com/2015/11/18/chemotherapy-in-aml/

Redactor: Larry H. Bernstein, MD, FCAP

5.5.4 Actualización sobre la leucemia mieloide crónica

https://pharmaceuticalintelligence.com/2015/10/14/update-on-chronic-myeloid-leukemia/

Redactor: Larry H. Bernstein, MD, FCAP

5.5.5 Rituximab para diversas neoplasias de linfocitos B

https://pharmaceuticalintelligence.com/2015/10/11/rituximab-for-a-variety-of-b-cell-malignancies/

Redactor: Larry H. Bernstein, MD, FCAP

5.5.6 Respuestas inmunitarias mediadas por linfocitos T y vías señalización activadas por los TLR

https://pharmaceuticalintelligence.com/2015/09/07/t-cell-mediated-immune-responses-signaling-pathways-activated-by-tlrs/

Redactor: Larry H. Bernstein, MD, FCAP

5.5.7 Expresión génica y mecanismos de resistencia inmunitaria adaptativa en el linfoma

https://pharmaceuticalintelligence.com/2015/10/20/gene-expression-and-adaptive-immune-resistance-mechanisms-in-lymphoma/

Redactor: Larry H. Bernstein, MD, FCAP

5.5.8 El sunitinib consigue la remisión de la leucemia linfoblástica aguda (LLA) del adulto. Secuenciación del ARN y bloqueo del receptor FLT3

https://pharmaceuticalintelligence.com/2012/07/09/sunitinib-brings-adult-all-to-remission-rna-sequencing/

Redactor: Aviva Lev-Ari, PhD, RN

5.5.9 Manejo del linfoma folicular

https://pharmaceuticalintelligence.com/2015/11/05/management-of-follicular-lymphoma/

Redactor: Larry H. Bernstein, MD, FCAP

5.5.10 Expresión génica y mecanismos de resistencia inmunitaria adaptativa en el linfoma

https://pharmaceuticalintelligence.com/2015/10/20/gene-expression-and-adaptive-immune-resistance-mechanisms-in-lymphoma/

Redactor: Larry H. Bernstein, MD, FCAP

5.6 Otros tipos de cáncer

5.6.1 Tratamiento del cáncer de pulmón

https://pharmaceuticalintelligence.com/2015/11/06/lung-cancer-therapy/

Redactor: Larry H. Bernstein, MD, FCAP

5.6.2 Fármacos para el cáncer de pulmón no microcítico: ¿qué nos depara el futuro?

https://pharmaceuticalintelligence.com/2012/11/06/non-small-cell-lung-cancer-drugs-where-does-the-future-lie/

Redactor: Larry H. Bernstein, MD, FCAP

5.6.3 Cáncer de colon

https://pharmaceuticalintelligence.com/2013/04/30/colon-cancer/

Autor/editor: Tilda Barliya PhD

5.6.4 La ERGE y el adenocarcinoma de esófago

https://pharmaceuticalintelligence.com/2015/10/10/gerd-and-esophageal-adenocarcinoma/

Redactor: Larry H. Bernstein, MD, FCAP

5.6.5 Melanoma

https://pharmaceuticalintelligence.com/2015/11/04/melanoma/

Redactor: Larry H. Bernstein, MD, FCAP

5.6.6 Adenocarcinoma de duodeno. La historia de Nathalie: una odisea que arribó a buen puerto

https://pharmaceuticalintelligence.com/2016/07/30/nathalies-story-a-health-journey-with-a-happy-ending/

Autor: Gail S. Thornton, M.A.

5.7 Trasplante de órganos

5.7.1 La historia de Marcela: un trasplante de hígado regaló una vida

https://pharmaceuticalintelligence.com/2016/07/23/marcelas-story-a-liver-transplant-gives-the-gift-of-life/

Autor: Gail S. Thornton, M.A.

Capítulo 6: Factores que contribuyen al bienestar de un paciente comprometido

6.1 Nutrición: artículos de interés en Pharmaceuticalintelligence.com

https://pharmaceuticalintelligence.com/2016/03/28/nutrition-articles-of-note-pharmaceuticalintelligence-com/

Autor y redactor: Larry H. Bernstein, MD, FCAP y editor: Aviva Lev-Ari, PhD, RN

6.2 Epigenética, medio ambiente y cáncer: artículos de interés en Pharmaceuticalintelligence.com

https://pharmaceuticalintelligence.com/2016/03/28/epigenetics-environment-and-cancer-articles-of-note-pharmaceuticalintelligence-com/

Autor y redactor: Larry H. Bernstein, MD, FCAP y editor: Aviva Lev-Ari, PhD, RN

6.3 La relación del hipermetabolismo del estrés con las necesidades de proteínas esenciales

https://pharmaceuticalintelligence.com/2015/10/25/the-relationship-of-stress-hypermetabolism-to-essential-protein-needs/

Redactor: Larry H. Bernstein, MD, FCAP

6.4 Mecanismo de resistencia a los medicamentos antineoplásicos

https://pharmaceuticalintelligence.com/2015/11/05/cancer-drug-resistance-mechanism/

Redactor: Larry H. Bernstein, MD, FCAP

6.5 Bioquímica y dismetabolismo del envejecimiento y las enfermedades graves

https://pharmaceuticalintelligence.com/2015/11/19/biochemistry-and-dysmetabolism-of-aging-and-serious-illness/

Redactor: Larry H. Bernstein, MD, FCAP

6.6 Experiencia y alivio del dolor

https://pharmaceuticalintelligence.com/2016/03/25/experience-of-and-alleviation-of-pain/

Redactor: Larry H. Bernstein, MD, FCAP

Capítulo 7: Metabolómica y vitaminas

7.1 Metabolómica: sus aplicaciones en la investigación alimentaria y nutricional

https://pharmaceuticalintelligence.com/2013/05/12/metabolomics-its-applications-in-food-and-nutrition-research/

Reportero y editor: Sudipta Saha, Ph.D.

7.2 Neutracéuticos

https://pharmaceuticalintelligence.com/2015/03/04/neutraceuticals/

Autor y redactor: Larry H. Bernstein, MD, FCAP

Resumen

Larry H. Bernstein, MD, FCAP

Tercera parte

La voz de los supervivientes de la cirugía a corazón abierto

Capítulo 8: Cirugía cardíaca

8.1 La perspectiva de un paciente: Sobre la cirugía a corazón abierto, desde el diagnóstico y la intervención hasta la recuperación. ¡Un nuevo día, una nueva vida y muchas preguntas!

https://pharmaceuticalintelligence.com/2015/05/10/a-patients-perspective-on-open-heart-surgery-from-diagnosis-and-intervention-to-recovery/

Autor invitado: Ferez S. Nallaseth, Ph.D.

8.2 Operación de triple revascularización a los 69 años. La historia de Ralph: un animador de corazón

https://pharmaceuticalintelligence.com/2016/07/30/ralphs-story-an-entertainer-at-heart/

Autor: Gail S. Thornton, M.A.

8.3 Una gran innovación en el campo de la desobstrucción vascular: el dispositivo para desobstruir vasos sanguíneos, Patente de los Estados Unidos n.º 8.663.209

https://pharmaceuticalintelligence.com/2016/02/29/a-fantastic-vessel-clearing-innovation/

Autor invitado: Clifford Thornton

Resumen del volumen

Larry H. Bernstein, MD, FCAP

Epílogo

Larry H. Bernstein, MD, FCAP

Primer volumen:

La VOZ de los pacientes, los directores generales de los hospitales, los prestadores de servicios sanitarios, los cuidadores y las familias: experiencia personal en cuidados intensivos y procedimientos médicos invasivos

2017

The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures

En Amazon.com desde el 16/10/2017

https://www.amazon.com/dp/B076HGB6MZ

PART B:

The eTOCs in Bi-lingual format: Spanish and English in Text format

Serie E: Medicina centrada en el paciente

Asesor de contenidos de la serie: Larry H. Bernstein, MD, FCAP

Primer volumen:

La VOZ de los pacientes, los directores generales de los hospitales, los prestadores de servicios sanitarios, los cuidadores y las familias: experiencia personal en cuidados intensivos y procedimientos médicos invasivos

2017

Traducción a español

Montero Language Services

En Amazon.com desde el 16/10/2017

https://www.amazon.com/dp/B076HGB6MZ

Autor, redactor y editor

Larry H Bernstein, MD, FCAP

Director científico

Leaders in Pharmaceutical Business Intelligence, Northampton, MA

Larry.bernstein@gmail.com

Editor colaborador y autor

Gail S Thornton, MA, PhD(c)

Leaders in Pharmaceutical Business Intelligence, Nueva Jersey

gailsthornton@yahoo.com

Aviva Lev-Ari, PhD, RN

Redactora jefe de la serie de libros electrónicos BioMed

Leaders in Pharmaceutical Business Intelligence, Boston

avivalev-ari@alum.berkeley.edu

Series E: Patient-Centered Medicine

Series Content Consultant: Larry H Bernstein, MD, FCAP

Volume One:

The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures

2017

On Amazon.com since 10/16/2017

https://www.amazon.com/dp/B076HGB6MZ

Author, Curator and Editor

Larry H Bernstein, MD, FCAP

Chief Scientific Officer

Leaders in Pharmaceutical Business Intelligence, Northampton, MA

Larry.bernstein@gmail.com

and

Contributing Editor and Author

Gail S Thornton, MA, PhD(c)

Leaders in Pharmaceutical Business Intelligence, New Jersey

gailsthornton@yahoo.com

Aviva Lev-Ari, PhD, RN

Editor-in-Chief BioMed e-Series of e-Books

Leaders in Pharmaceutical Business Intelligence, Boston

avivalev-ari@alum.berkeley.edu

Lista de colaboradores y sus biografías

List of Contributors & Contributors’ Biographies

Larry H. Bernstein, MD, FCAP

Capítulo 2, 3.1, 3.2, 3.3, 3.4, 4.2, 5.1.1, 5.1.2, 5.2.1, 5.2.2, 5.2.3, 5.3.2, 5.5.1 – 5.5.7, 5.5.9, 5.5.10, 5.6.1, 5.6.4, 5.6.5, 6.1, 6.2, 6.3 – 6.6, 7.2

Chapter 2, 3.1, 3.2, 3.3, 3.4, 4.2, 5.1.1, 5.1.2, 5.2.1, 5.2.2, 5.2.3, 5.3.2, 5.5.1 – 5.5.7, 5.5.9, 5.5.10, 5.6.1, 5.6.4, 5.6.5, 6.1, 6.2, 6.3 – 6.6, 7.2

Gail S Thornton, MA, PhD(c)

2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 5.4.3, 5.6.6, 5.7.1, 8.2

Aviva Lev-Ari, PhD, RN

Prefacio, 1.1, 4.1, 5.1.2, 5.5.8, 6.1, 6.2,

Preface, 1.1, 4.1, 5.1.2, 5.5.8, 6.1, 6.2,

Stephen J. Williams, PhD

1.2, 1.3, 5.4.1, 5.4.2,

Demet Sag, PhD

1.4

Ritu Saxena, PhD

5.6.2,

Tilda Barliya, PhD

5.6.3

Sudipta Saha, PhD

7.1

AUTORES INVITADOS

GUEST AUTHORS

Autor invitado: Ferez Nallaseth, PhD

Guest Author: Ferez Nallaseth, PhD

8.1

Autor invitado: Itzhak Brook MD, MSc, Departamento de Pediatría, Facultad de Medicina de la Universidad de Georgetown, Washington DC

Guest Author: Itzhak Brook MD, MSc, Department of Pediatrics, Georgetown University School of Medicine Washington DC

1.5

Autor invitado: Clifford Thornton

Guest Author: Clifford Thornton

8.3

Los enlaces indicados llevan al contenido original en inglés

MD	Licenciado/a en medicina y cirugía (Estados Unidos)
PhD	Doctorado/a
RN	Enfermero/a titulado/a (National Board of Nursing Registration)
FCAP	Miembro distinguido (Fellow) del Colegio de Anatomopatólogos de los Estados Unidos
M.A.	M.A.

Indice de contenidos electrónico (IDCe)

electronic Table of Contents

Prefacio por Aviva Lev-Ari, PhD, RN

Introducción del volumen por Larry H. Bernstein, MD, FCAP

Preface by Aviva Lev-Ari, PhD, RN

Volume Introduction by Larry H. Bernstein, MD, FCAP

Primera parte:

Percepción de la atención sanitaria

Part One:

Perceptions of Care

Introducción

Larry H. Bernstein, MD, FCAP

Introduction

Larry H. Bernstein, MD, FCAP

Capítulo 1: Impresiones personales

Chapter 1: Personal Accounts

1.1 La historia personal de JL y la secuenciación de su genoma completo

1.1 Personal Tale of JL’s Whole Genome Sequencing

https://pharmaceuticalintelligence.com/2012/11/24/personal-tale-of-jls-whole-genome-sequencing/

Reportero: Aviva Lev-Ari, PhD, RN

Reporter: Aviva Lev-Ari, PhD, RN

1.2 Notas en directo de la reunión #cbi16 de AACR sobre medicina de precisión: 5:10 p.m. Gran idea, la historia de una superviviente

1.2 Live Notes from @AACR’s #cbi16 Meeting on Precision Medicine: 5:10PM Big Idea A survivor’s Story

https://pharmaceuticalintelligence.com/2016/02/17/live-notes-from-aacrs-cbi16-meeting-on-precision-medicine-510pm-big-idea-a-survivors-story/

Reportero: Stephen J. Williams, Ph.D.

Reporter: Stephen J. Williams, Ph.D.

1.3 Notas en directo de la reunión #cbi16 de AACR sobre medicina de precisión: historia de éxito y el Dr. Stephan Grupp

1.3 Live Notes from @AACR’s #cbi16 Meeting on Precision Medicine: Success Story and Dr. Stephan Grupp

https://pharmaceuticalintelligence.com/2016/01/21/live-notes-from-aacrs-cbi16-meeting-on-precision-medicine-success-story-and-dr-stephen-grupp/

Reportero: Stephen J. Williams, Ph.D.

Reporter: Stephen J. Williams, Ph.D.

1.4 Tratamientos paliativos: mantener la mente fuerte durante el cáncer

1.4 Supportive Treatments: Hold the Mind Strong During Cancer

https://pharmaceuticalintelligence.com/2015/11/03/supportive-treatments-hold-the-mind-strong-during-cancer/

Autor: Demet Sag, PhD

Author: Demet Sag, PhD

1.5 Encontrar mi voz: la historia de un laringectomizado

1.5 Finding My Voice: A Laryngectomee’s Story

https://pharmaceuticalintelligence.com/2016/05/08/finding-my-voice-a-laryngectomee-laryngectomy-story/

Autor invitado: Itzhak Brook MD, MSc, Departamento de Pediatría, Facultad de Medicina de la Universidad de Georgetown, Washington DC

Guest Author: Itzhak Brook MD, MSc, Department of Pediatrics, Georgetown University School of Medicine Washington DC

Capítulo 2: Artículos sobre la percepción de la atención sanitaria

Chapter 2: Articles on Perception of Care

Introducción

Larry H. Bernstein, MD, FCAP

Introduction

Larry H. Bernstein, MD, FCAP

2.1 La prestación de atención sanitaria. Fuentes externas. Se dejan intencionadamente como referencias en los enlaces.

2.1 Delivery of Care – External Sources – Intentionally are Left as References in Live Links.

Track, trigger and teamwork: Communication of deterioration in acute medical and surgical wards Article

Intensive and Critical Care Nursing, Volume 26, Issue 1, Pages 10-17

Donohue, L.A.; Endacott, R.

Cited by Scopus (19)

Communication interaction in ICU-Patient and staff experiences and perceptions Article

Intensive and Critical Care Nursing, Volume 22, Issue 3, Pages 167-180

Magnus, V.S.; Turkington, L.

Cited by Scopus (39)

Nursing care in a high-technological environment: Experiences of critical care nurses Article

Intensive and Critical Care Nursing, Volume 31, Issue 2, Pages 116-123

Tunlind, A.; Granstrom, J.; Engstrom, A.

Knowledge, attitudes and barriers towards prevention of pressure ulcers in intensive care units: A descriptive cross-sectional study Article

Intensive and Critical Care Nursing, Volume 26, Issue 6, Pages 335-342

Strand, T.; Lindgren, M.

Rehabilitation during mechanical ventilation: Review of the recent literature Review article

Intensive and Critical Care Nursing, Volume 31, Issue 3, Pages 125-132

Ntoumenopoulos, G.

Reducing risk for ventilator associated pneumonia through nursing sensitive interventions Article

Intensive and Critical Care Nursing, Volume 29, Issue 5, Pages 261-265

Micik, S.; Besic, N.; Johnson, N.; Han, M.; Hamlyn, S.; Ball, H.

The lived experiences of adult intensive care patients who were conscious during mechanical ventilation: A phenomenological-hermeneutic study Article

Intensive and Critical Care Nursing, Volume 28, Issue 1, Pages 6-15

Karlsson, V.; Bergbom, I.; Forsberg, A.

Families’experiences of their interactions with staff in an Australian intensive care unit (ICU): A qualitative study Article

Intensive and Critical Care Nursing, Volume 31, Issue 1, Pages 51-63

Wong, P.; Liamputtong, P.; Koch, S.; Rawson, H.

Experiences of critically ill patients in the ICU Article

Intensive and Critical Care Nursing, Volume 24, Issue 5, Pages 300-313

Hofhuis, J.G.M.; Spronk, P.E.; van Stel, H.F.; Schrijvers, A.J.P.; Rommes, J.H.; Bakker, J.

Cited by Scopus (54)

2.2 Director general de un hospital. Un nuevo estándar en la atención sanitaria: el Hospital Farrer Park, el primer complejo sanitario y hotelero totalmente integrado de Singapur

2.2 Hospital CEO: A New Standard in Health Care – Farrer Park Hospital, Singapore’s First Fully Integrated Healthcare/Hospitality Complex

https://pharmaceuticalintelligence.com/2016/06/22/a-new-standard-in-health-care-farrer-park-hospital-singapores-first-fully-integrated-healthcarehospitality-complex/

Autor: Gail S. Thornton, M.A.

Author: Gail S. Thornton, M.A.

2.3 Descubrimiento de fármacos para la cura del cáncer: valor para los pacientes. Aplicación de los avances científicos: estudio de caso de una empresa farmacéutica líder mundial, Astellas Pharma Inc.

2.3 Drug Discovery for Cancer Cure: Value for Patients – Turning Advances in Science: A Case Study of a Leading Global Pharmaceutical Company – Astellas Pharma Inc.

https://pharmaceuticalintelligence.com/2016/08/24/value-for-patients-turning-advances-in-science-a-case-study-of-a-leading-global-pharmaceutical-company-astellas-pharma-inc/

Autor: Gail S. Thornton, M.A.

Author: Gail S. Thornton, M.A.

2.4 Director general de un hospital. Una rica tradición de atención centrada en el paciente: el Centro Médico de la Universidad de Richmond, líder en atención sanitaria y formación médica de Nueva York

2.4 Hospital CEO: A Rich Tradition of Patient-Focused Care — Richmond University Medical Center, New York’s Leader in Health Care and Medical Education

https://pharmaceuticalintelligence.com/2016/10/17/a-rich-tradition-of-patient-focused-care-richmond-university-medical-center-new-yorks-leader-in-health-care-and-medical-education/

Autor: Gail S. Thornton, M.A.

Author: Gail S. Thornton, M.A.

2.5 Director general de un hospital. Hospital Infantil Universitario de Zúrich (Universitäts-Kinderspital Zürich), Suiza: un destacado centro de investigación y medicina pediátrica

2.5 Hospital CEO: University Children’s Hospital Zurich (Universitäts-Kinderspital Zürich), Switzerland – A Prominent Center of Pediatric Research and Medicine

https://pharmaceuticalintelligence.com/2016/12/21/university-childrens-hospital-zurich-universitats-kinderspital-zurich-switzerland-a-prominent-center-of-pediatric-research-and-medicine/

Autor: Gail S. Thornton, M.A.

Author: Gail S. Thornton, M.A.

2.6 Director general de un hospital. Centro Suizo de Parapléjicos, Nottwil, Suiza: una clínica referente mundial para las lesiones medulares

2.6 Hospital CEO: Swiss Paraplegic Centre, Nottwil, Switzerland – A World-Class Clinic for Spinal Cord Injuries

https://pharmaceuticalintelligence.com/2017/03/23/swiss-paraplegic-centre-nottwil-switzerland-a-world-class-clinic-for-spinal-cord-injuries/

Autor: Gail S. Thornton, M.A.

Author: Gail S. Thornton, M.A.

2.7 Director de un instituto de investigación: el Instituto de Salud Global de Rutgers, parte de la facultad de Ciencias Biomédicas y de la Salud de la Universidad de Rutgers, New Brunswick, Nueva Jersey. Una nueva empresa diseñada para mejorar la salud y el bienestar a nivel mundial

2.7 Institute Director: The Rutgers Global Health Institute, part of Rutgers Biomedical and Health Sciences, Rutgers University, New Brunswick, New Jersey – A New Venture Designed to Improve Health and Wellness Globally

Autor: Gail S. Thornton, M.A.

Author: Gail S. Thornton, M.A.

2.8 Rector y director científico de un centro: City of Hope, Duarte, California. Combinando la ciencia con el alma para obrar milagros en un centro oncológico integral designado por el Instituto Nacional del Cáncer. Una entrevista con el rector y director científico de City of Hope, Steven T. Rosen, M.D.

2.8 Center’s Provost & CSO: City of Hope, Duarte, California – Combining Science with Soul to Create Miracles at a Comprehensive Cancer Center designated by the National Cancer Institute – An Interview with the Provost and Chief Scientific Officer of City of Hope, Steven T. Rosen, M.D.

Autor: Gail S. Thornton, M.A.

Author: Gail S. Thornton, M.A.

2.9 El futuro de los hospitales: cómo colaboran la asistencia médica y la tecnología para mejorar la atención al paciente

2.9 The Future of Hospitals – How Medical Care and Technology Work Together to Advance Patient Care

https://pharmaceuticalintelligence.com/2017/05/31/the-future-of-hospitals-how-medical-care-and-technology-work-together-to-advance-patient-care/

Autor: Gail S. Thornton, M.A.

Author: Gail S. Thornton, M.A.

Resumen

Larry H. Bernstein, MD, FCAP

Summary

Larry H. Bernstein, MD, FCAP

Segunda parte:

La voz de los supervivientes del cáncer

Part Two:

The Voice of Cancer Survivors

Capítulo 3: Un diagnóstico llamado «CÁNCER»

Chapter 3: A Diagnosis called “CANCER”

Introducción

Larry H. Bernstein, MD, FCAP

Introduction

Larry H. Bernstein, MD, FCAP

3.1 Diagnóstico complementario del cáncer

3.1 Cancer Companion Diagnostics

https://pharmaceuticalintelligence.com/2015/11/14/cancer-companion-diagnostics/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

3.2 Los ARN largos no codificantes en los cánceres humanos

3.2 lncRNAs in Human Cancers

https://pharmaceuticalintelligence.com/2015/10/13/lncrnas-in-human-cancers/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

3.3 Un ensayo de biopsia líquida podría predecir la resistencia a los fármacos

3.3 Liquid Biopsy Assay May Predict Drug Resistance

https://pharmaceuticalintelligence.com/2015/11/06/liquid-biopsy-assay-may-predict-drug-resistance/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

3.4 Biomarcadores farmacogenómicos para el tratamiento personalizado del cáncer

3.4 Pharmacogenomic Biomarkers for Personalized Cancer Treatment

https://pharmaceuticalintelligence.com/2015/10/09/pharmacogenomic-biomarkers-for-personalized-cancer-treatment-3-7/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

Capítulo 4: Experiencia de los pacientes con la cirugía invasiva y la cirugía mínimamente invasiva

Chapter 4: Patients Experience with Invasive Surgery and Minimally Invasive Surgery

4.1 Medicina personalizada: biología celular del cáncer y cirugía mínimamente invasiva (CMI)

4.1 Personalized Medicine: Cancer Cell Biology and Minimally Invasive Surgery (MIS)

https://pharmaceuticalintelligence.com/2012/12/01/personalized-medicine-cancer-cell-biology-and-minimally-invasive-surgery-mis/

Redactor: Aviva Lev-Ari, PhD, RN

Curator: Aviva Lev-Ari, PhD, RN

4.2 Cardiotoxicidad y miocardiopatía por efectos adversos de medicamentos

4.2 Cardiotoxicity and Cardiomyopathy Related to Drugs Adverse Effects

https://pharmaceuticalintelligence.com/2013/04/11/cardiotoxicity-and-cardiomyopathy-related-to-drugs-adverse-effects/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

Capítulo 5: Tipos de cáncer y experiencia de los pacientes

Chapter 5: Cancer Types – Patients Experience

5.1 Cáncer tiroideo

5.1 Thyroid Cancer

5.1.1 Experiencia con el cáncer de tiroides

5.1.1 Experience with Thyroid Cancer

https://pharmaceuticalintelligence.com/2015/11/23/my-experience-with-thyroid-cancer/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

5.1.2 Vías de señalización del cáncer y progresión tumoral: imágenes de procesos biológicos explicadas por un patólogo experto en cáncer

5.1.2 Cancer Signaling Pathways and Tumor Progression: Images of Biological Processes in the Voice of a Pathologist Cancer Expert

https://pharmaceuticalintelligence.com/2015/06/09/cancer-signaling-pathways-and-tumor-progression-images-of-biological-processes-in-the-voice-of-a-pathologist-cancer-expert/

Autor y redactor de la ilustración: Larry H Bernstein, MD, FCAP y editor: Aviva Lev-Ari, PhD, RN

Author and Illustration Curator: Larry H Bernstein, MD, FCAP and Curator: Aviva Lev-Ari, PhD, RN

5.2 Cirugía cerebral

5.2 Brain Surgery

5.2.1 La experiencia de un primo con una acromegalia hipofisaria

5.2.1 A Cousin’s Experience with a Pituitary Acromegaly

https://pharmaceuticalintelligence.com/2015/11/23/my-cousins-experience-with-a-pituitary-acromegaly/

Autor: Larry H. Bernstein, MD, FCAP

Author: Larry H. Bernstein, MD, FCAP

5.2.2 Pérdida de la regulación normal del crecimiento

5.2.2 Loss of Normal Growth Regulation

https://pharmaceuticalintelligence.com/2014/07/06/loss-of-normal-growth-regulation/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

5.2.3 Glioma, glioblastoma y neurooncología

5.2.3 Glioma, Glioblastoma and Neurooncology

https://pharmaceuticalintelligence.com/2015/10/19/glioma-glioblastoma-and-neurooncology/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

5.3 Cáncer de mama

5.3 Breast Cancer

5.3.1 Las caras del cáncer de mama. Encuentra tu historia y únete a la conversación

5.3.1 Faces of Breast Cancer – Find Your Story, Join the Conversation

Por TARA PARKER-POPE – –

By TARA PARKER-POPE –

https://pharmaceuticalintelligence.com/2015/02/19/faces-of-breast-cancer/

5.3.2 Una decisión emocional y reflexiva sobre el BRCA1 y la cirugía

5.3.2 An Emotional and Thoughtful Decision Over BRAC1 and Surgery

https://pharmaceuticalintelligence.com/2015/11/24/an-emotional-and-thoughtful-decision-over-brac1-and-surgery/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

5.4 Cáncer de ovario

5.4 Ovarian Cancer

5.4.1 Una historia resumida de la ciencia que hay detrás del ensayo del β-bloqueante para el tratamiento del cáncer de ovario

5.4.1 A Curated History of the Science Behind the Ovarian Cancer β-Blocker Trial

https://pharmaceuticalintelligence.com/2015/10/26/a-curated-history-of-the-science-behind-the-ovarian-cancer-%CE%B2-blocker-trial/

Redactor: Stephen J. Williams, Ph.D.

Curator: Stephen J. Williams, Ph.D.

5.4.2 Buenas y malas noticias sobre el tratamiento del cáncer de ovario

5.4.2 Good and Bad News Reported for Ovarian Cancer Therapy

https://pharmaceuticalintelligence.com/2014/07/01/good-and-bad-news-reported-for-ovarian-cancer-therapy-2/

Reportero y editor: Stephen J. Williams, Ph.D.

Reporter and Curator: Stephen J. Williams, Ph.D.

5.4.3 La historia de Almudena: una vida de esperanza, rejuvenecimiento y fuerza

5.4.3 Almudena’s Story: A Life of Hope, Rejuvenation and Strength

https://pharmaceuticalintelligence.com/2016/08/10/almudenas-story-a-life-of-hope-rejuvenation-and-strength/

Autor: Gail S. Thornton, M.A.

Author: Gail S. Thornton, M.A.

5.5 Neoplasias hematológicas malignas

5.5 Hematological Malignancies

5.5.1 Diagnóstico de las neoplasias hematológicas malignas

5.5.1 Hematological Malignancy Diagnostics

https://pharmaceuticalintelligence.com/2015/08/11/hematological-malignancy-diagnostics-4-2-3/

Autor y redactor: Larry H. Bernstein, MD, FCAP

Author and Curator: Larry H. Bernstein, MD, FCAP

5.5.2 Clasificación de los cánceres hematológicos

5.5.2 Hematological Cancer Classification

https://pharmaceuticalintelligence.com/2015/08/11/hematological-cancer-classification-2-4/

Autor y redactor: Larry H. Bernstein, MD, FCAP

Author and Curator: Larry H. Bernstein, MD, FCAP

5.5.3 Quimioterapia en la LMA

5.5.3 Chemotherapy in AML

https://pharmaceuticalintelligence.com/2015/11/18/chemotherapy-in-aml/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

5.5.4 Actualización sobre la leucemia mieloide crónica

5.5.4 Update on Chronic Myeloid Leukemia

https://pharmaceuticalintelligence.com/2015/10/14/update-on-chronic-myeloid-leukemia/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

5.5.5 Rituximab para diversas neoplasias de linfocitos B

5.5.5 Rituximab for a variety of B-cell malignancies

https://pharmaceuticalintelligence.com/2015/10/11/rituximab-for-a-variety-of-b-cell-malignancies/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

5.5.6 Respuestas inmunitarias mediadas por linfocitos T y vías señalización activadas por los TLR

5.5.6 T cell-mediated immune responses & signaling pathways activated by TLRs

https://pharmaceuticalintelligence.com/2015/09/07/t-cell-mediated-immune-responses-signaling-pathways-activated-by-tlrs/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

5.5.7 Expresión génica y mecanismos de resistencia inmunitaria adaptativa en el linfoma

5.5.7 Gene expression and adaptive immune resistance mechanisms in lymphoma

https://pharmaceuticalintelligence.com/2015/10/20/gene-expression-and-adaptive-immune-resistance-mechanisms-in-lymphoma/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

5.5.8 El sunitinib consigue la remisión de la leucemia linfoblástica aguda (LLA) del adulto. Secuenciación del ARN y bloqueo del receptor FLT3

5.5.8 Sunitinib brings Adult Acute Lymphoblastic Leukemia (ALL) to Remission – RNA Sequencing – FLT3 Receptor Blockade

https://pharmaceuticalintelligence.com/2012/07/09/sunitinib-brings-adult-all-to-remission-rna-sequencing/

Redactor: Aviva Lev-Ari, PhD, RN

Curator: Aviva Lev-Ari, PhD, RN

5.5.9 Manejo del linfoma folicular

5.5.9 Management of Follicular Lymphoma

https://pharmaceuticalintelligence.com/2015/11/05/management-of-follicular-lymphoma/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

5.5.10 Expresión génica y mecanismos de resistencia inmunitaria adaptativa en el linfoma

5.5.10 Gene Expression and Adaptive Immune Resistance Mechanisms in Lymphoma

https://pharmaceuticalintelligence.com/2015/10/20/gene-expression-and-adaptive-immune-resistance-mechanisms-in-lymphoma/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

5.6 Otros tipos de cáncer

5.6 Other Types of Cancer

5.6.1 Tratamiento del cáncer de pulmón

5.6.1 Lung Cancer Therapy

https://pharmaceuticalintelligence.com/2015/11/06/lung-cancer-therapy/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

5.6.2 Fármacos para el cáncer de pulmón no microcítico: ¿qué nos depara el futuro?

5.6.2 Non-small Cell Lung Cancer drugs – where does the Future lie?

https://pharmaceuticalintelligence.com/2012/11/06/non-small-cell-lung-cancer-drugs-where-does-the-future-lie/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

5.6.3 Cáncer de colon

5.6.3 Colon Cancer

https://pharmaceuticalintelligence.com/2013/04/30/colon-cancer/

Autor/editor: Tilda Barliya PhD

Author/Editor: Tilda Barliya PhD

5.6.4 La ERGE y el adenocarcinoma de esófago

5.6.4 GERD and esophageal adenocarcinoma

https://pharmaceuticalintelligence.com/2015/10/10/gerd-and-esophageal-adenocarcinoma/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

5.6.5 Melanoma

https://pharmaceuticalintelligence.com/2015/11/04/melanoma/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

5.6.6 Adenocarcinoma de duodeno. La historia de Nathalie: una odisea que arribó a buen puerto

5.6.6 Adenocarcinoma of the Duodenum – Nathalie’s Story: A Health Journey With A Happy Ending

https://pharmaceuticalintelligence.com/2016/07/30/nathalies-story-a-health-journey-with-a-happy-ending/

Autor: Gail S. Thornton, M.A.

Author: Gail S. Thornton, M.A.

5.7 Trasplante de órganos

5.7 Organ Transplantation

5.7.1 La historia de Marcela: un trasplante de hígado regaló una vida

5.7.1 Marcela’s Story: A Liver Transplant Gives the Gift of Life

https://pharmaceuticalintelligence.com/2016/07/23/marcelas-story-a-liver-transplant-gives-the-gift-of-life/

Autor: Gail S. Thornton, M.A.

Author: Gail S. Thornton, M.A.

Capítulo 6: Factores que contribuyen al bienestar de un paciente comprometido

Chapter 6: Contributing Factors to A Compromised Patient’s Wellbeing

6.1 Nutrición: artículos de interés en Pharmaceuticalintelligence.com

6.1 Nutrition: Articles of Note @PharmaceuticalIntelligence.com

https://pharmaceuticalintelligence.com/2016/03/28/nutrition-articles-of-note-pharmaceuticalintelligence-com/

Autor y redactor: Larry H. Bernstein, MD, FCAP y editor: Aviva Lev-Ari, PhD, RN

Author and Curator: Larry H. Bernstein, MD, FCAP and Curator: Aviva Lev-Ari, PhD, RN

6.2 Epigenética, medio ambiente y cáncer: artículos de interés en Pharmaceuticalintelligence.com

6.2 Epigenetics, Environment and Cancer: Articles of Note @PharmaceuticalIntelligence.com

https://pharmaceuticalintelligence.com/2016/03/28/epigenetics-environment-and-cancer-articles-of-note-pharmaceuticalintelligence-com/

Autor y redactor: Larry H. Bernstein, MD, FCAP y editor: Aviva Lev-Ari, PhD, RN

Author and Curator: Larry H. Bernstein, MD, FCAP and Curator: Aviva Lev-Ari, PhD, RN

6.3 La relación del hipermetabolismo del estrés con las necesidades de proteínas esenciales

6.3 The relationship of stress hypermetabolism to essential protein needs

https://pharmaceuticalintelligence.com/2015/10/25/the-relationship-of-stress-hypermetabolism-to-essential-protein-needs/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

6.4 Mecanismo de resistencia a los medicamentos antineoplásicos

6.4 Cancer Drug-Resistance Mechanism

https://pharmaceuticalintelligence.com/2015/11/05/cancer-drug-resistance-mechanism/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

6.5 Bioquímica y dismetabolismo del envejecimiento y las enfermedades graves

6.5 Biochemistry and Dysmetabolism of Aging and Serious Illness

https://pharmaceuticalintelligence.com/2015/11/19/biochemistry-and-dysmetabolism-of-aging-and-serious-illness/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

6.6 Experiencia y alivio del dolor

6.6 Experience of and Alleviation of Pain

https://pharmaceuticalintelligence.com/2016/03/25/experience-of-and-alleviation-of-pain/

Redactor: Larry H. Bernstein, MD, FCAP

Curator: Larry H. Bernstein, MD, FCAP

Capítulo 7: Metabolómica y vitaminas

Chapter 7: Metabolomics & Vitamins

7.1 Metabolómica: sus aplicaciones en la investigación alimentaria y nutricional

7.1 Metabolomics: its applications in food and nutrition research

https://pharmaceuticalintelligence.com/2013/05/12/metabolomics-its-applications-in-food-and-nutrition-research/

Reportero y editor: Sudipta Saha, Ph.D.

Reporter and Curator: Sudipta Saha, Ph.D.

7.2 Neutracéuticos

7.2 Neutraceuticals

https://pharmaceuticalintelligence.com/2015/03/04/neutraceuticals/

Autor y redactor: Larry H. Bernstein, MD, FCAP

Author and Curator: Larry H Bernstein, MD, FCAP

Resumen

Summary

Larry H. Bernstein, MD, FCAP

Tercera parte

La voz de los supervivientes de la cirugía a corazón abierto

Part Three

The Voice of Open Heart Surgery Survivors

Capítulo 8: Cirugía cardíaca

Chapter 8: Cardiac Surgery

8.1 La perspectiva de un paciente: Sobre la cirugía a corazón abierto, desde el diagnóstico y la intervención hasta la recuperación. ¡Un nuevo día, una nueva vida y muchas preguntas!

8.1 A Patient’s Perspective: On Open Heart Surgery from Diagnosis and Intervention to Recovery – A New Day, a New Lease and Unfolding Questions!

https://pharmaceuticalintelligence.com/2015/05/10/a-patients-perspective-on-open-heart-surgery-from-diagnosis-and-intervention-to-recovery/

Autor invitado: Ferez S. Nallaseth, Ph.D.

Guest Author: Ferez S. Nallaseth, Ph.D.

8.2 Operación de triple revascularización a los 69 años. La historia de Ralph: un animador de corazón

8.2 Triple-bypass operation at age 69 – Ralph’s Story: An Entertainer at Heart

https://pharmaceuticalintelligence.com/2016/07/30/ralphs-story-an-entertainer-at-heart/

Autor: Gail S. Thornton, M.A.

Author: Gail S. Thornton, M.A.

8.3 Una gran innovación en el campo de la desobstrucción vascular: el dispositivo para desobstruir vasos sanguíneos, Patente de los Estados Unidos n.º 8.663.209

8.3 A Fantastic Vessel-Clearing Innovation on The vessel-clearing device, U.S. Patent No. 8,663,209

https://pharmaceuticalintelligence.com/2016/02/29/a-fantastic-vessel-clearing-innovation/

Autor invitado: Clifford Thornton

Guest Author: Clifford Thornton

Resumen del volumen

Volume Summary

Larry H. Bernstein, MD, FCAP

Epílogo

Epilogue

Larry H. Bernstein, MD, FCAP

Primer volumen:

La VOZ de los pacientes, los directores generales de los hospitales, los prestadores de servicios sanitarios, los cuidadores y las familias: experiencia personal en cuidados intensivos y procedimientos médicos invasivos

2017

The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures

En Amazon.com desde el 16/10/2017

https://www.amazon.com/dp/B076HGB6MZ

PART C:

The Editorials of the original e-Books in English in Audio format

Series E: Patient-Centered Medicine

Series Content Consultant: Larry H Bernstein, MD, FCAP

Volume One:

The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures

2017

On Amazon.com since 10/16/2017

https://www.amazon.com/dp/B076HGB6MZ

Author, Curator and Editor

Larry H Bernstein, MD, FCAP

Chief Scientific Officer

Leaders in Pharmaceutical Business Intelligence, Northampton, MA

Larry.bernstein@gmail.com

and

Contributing Editor and Author

Gail S Thornton, MA, PhD(c)

Leaders in Pharmaceutical Business Intelligence, New Jersey

gailsthornton@yahoo.com

Aviva Lev-Ari, PhD, RN

Editor-in-Chief BioMed e-Series of e-Books

Leaders in Pharmaceutical Business Intelligence, Boston

avivalev-ari@alum.berkeley.edu

List of Contributors & Contributors’ Biographies

Larry H. Bernstein, MD, FCAP

Chapter 2, 3.1, 3.2, 3.3, 3.4, 4.2, 5.1.1, 5.1.2, 5.2.1, 5.2.2, 5.2.3, 5.3.2, 5.5.1 – 5.5.7, 5.5.9, 5.5.10, 5.6.1, 5.6.4, 5.6.5, 6.1, 6.2, 6.3 – 6.6, 7.2

Gail S Thornton, MA, PhD(c)

2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 5.4.3, 5.6.6, 5.7.1, 8.2

Aviva Lev-Ari, PhD, RN

Preface, 1.1, 4.1, 5.1.2, 5.5.8, 6.1, 6.2,

Stephen J. Williams, PhD

1.2, 1.3, 5.4.1, 5.4.2,

Demet Sag, PhD

1.4

Ritu Saxena, PhD

5.6.2,

Tilda Barliya, PhD

5.6.3

Sudipta Saha, PhD

7.1

GUEST AUTHORS

Guest Author: Ferez Nallaseth, PhD

8.1

Guest Author: Itzhak Brook MD, MSc, Department of Pediatrics, Georgetown University School of Medicine Washington DC

1.5

Guest Author: Clifford Thornton

8.3

electronic Table of Contents

Preface by Aviva Lev-Ari, PhD, RN

This volume is the first in a four-volumes e-Series on Patient-Centered Medicine. There are narratives by Patients and there are accounts by Health Care Providers. This volume is unique in the body of existing literature on the subject matter, in the exposition effort to incorporate in tandem, the VOICES of Patients on their Personal Experience with Critical Care and Invasive Medical Procedures. We provide the Personal views of Hospitals CEOs, Health Care Providers, Caregivers and Families in conjunction with the voices of the Patients.

This Volume represents PRIMARY RESEARCH attained by two methodologies:

One, Personal Interviews conducted by the volume Co-Editor, Gail S. Thornton, with Patients and their families facing the diagnosis of a serious medical (not Terminal) illness requiring a major surgery. Ms. Thornton conducted interviews with Hospitals CEOs and other leaders of several Health Care Providers in the US and in other countries.

The other, Personal Accounts and Testimonies of Patients written by themselves. Some are MDs diagnosed with Cancer, had undergone invasive surgeries as an organ excision, some underwent Open Heart Surgery.

Larry H. Bernstein, MD, FCAP

This volume is divided into three parts: perceptions of care, the voice of cancer survivors, and the voice of open heart surgery survivors. This is quite difficult because of variation in patients’ ages, outlooks, chronicity and type of condition, and adverse effects of treatments. The best that we can do is look at a small number of narratives.

Volume Introduction

Larry H. Bernstein, MD, FCAP

Perceptions of care are determined by a number of important factors that are dependent on the individual and on the physician, and on the treatment conditions. The individual factors include, but are not limited to patient social status, linguistic factors, cognitive skills and level of education, and communication skills of the care providers. The facilities can be a factor not easily ranked, although that is always a matter for debate. The voices of cancer survivors are presented for both cancer and cardiovascular surgery. These are quite variable and are highly dependent on the specialty treatment organization.

Part One:

Perceptions of Care

Introduction

Larry H. Bernstein, MD, FCAP

The perception of care is importantly a personal matter. On the one hand, a young person who has undergone a series of procedures with unsatisfied relief, young or old, goes through a defined series of stages described in Death and Dying. In the early stages of healing the outlook may be good. The perceptions that are most vivid are related to comprehension of the seriousness of the illness, the satisfaction of the attention provided by the caregiver, and the immediate surroundings. Complications may ensue during the course of treatment, and a series of complications can be demoralizing. A not often recognized factor is the personal contact with family and friends, which can make a huge difference in the experience. Even when the contact is not at the bedside, daily and weekly phone contact is supportive. An undesirable feature of current situations is directly related to facilities management, crowding, nurse/patient ratio, the amount of time required for electronic health records review in competition with real time caring for patients.

Three-part ‘Cancer: Emperor of All Maladies’ documentary to debut in late March 2015.

The oncology “community” is apparently jumping at the chance to show support for documentary filmmaker Ken Burns‘ latest PBS project — a 6-hour film examining the history of cancer.

Genentech, Bristol-Myers Squibb, Siemens, Cancer Treatment Centers of America, the American Cancer Society, the Leukemia and Lymphoma Society, and the American Association for Cancer Research — have either helped bankroll or support the production and/or the publicity effort around the film, titled “Cancer: the Emperor of All Maladies.”

And in the run-up to the scheduled airing in late March, a number of those supporters are organizing pre-screening events — starting today with a special half-hour program hosted by Katie Couric, the global news anchor for Yahoo! News and a Stand Up To Cancer (SU2C) co-founder. The Couric program will be available at CancerFilms.org and will be broadcast later by about 30 PBS affiliate stations.

The documentary itself is based on the 2010 Pulitzer prize-winning book “The Emperor of All Maladies: A Biography of Cancer” by Siddhartha Mukherjee, MD, PhD.

The Entertainment Industry Foundation (EIF) and its SU2C initiative and WETA-TV, the Washington, D.C., PBS station, spearheaded the production and are coordinating outreach efforts.

EIF obtained the television and film rights for Mukherjee’s book soon after its publication (and prior to its Pulitzer) at the urging of the late producer Laura Ziskin, one of SU2C’s co-founders, who read the book when she was undergoing treatment for metastatic breast cancer. EIF then persuaded Burns to produce a documentary based on it.

SOURCE

https://www.medpagetoday.com/hematologyoncology/othercancers/50072?xid=nl_mpt_DHE_2015-02-18&utm_content=&eun=g99985d0r&userid=99985&mu_id=5099207&utm_term=Daily

Chapter 1: Personal Accounts

Chapter 2: Articles on Perception of Care

Introduction

Larry H. Bernstein, MD, FCAP

In the first chapter there were examples of patient experiences in receiving care. This second portion gets to the driving factors in an institution that make a difference. There are changes in shifts, and there are nurse, dietitians, physician assistants, perhaps hospitalist and specialist physicians all involved in the patient’s care. Then there are visiting hours, family, and next of kin. These interactions are discussed here.

Summary

Larry H. Bernstein, MD, FCAP

I have tried to give a two sided perspective on the patient perspective and on the interactions that can be attended to for improving patient care and the perception of care in a complex environment in which nurses, physicians and hospital staff are attending to the patient’s needs, whether it is the emergency department, intensive care unit, clinic, operating room, cath lab, or other location in the healthcare setting.

Part Two:

The Voice of Cancer Survivors

Introduction

Larry H. Bernstein, MD, FCAP

Cancer survival is a difficult matter. Medicine a century ago was focused on infectious disease. There were recurrences of war, famine and pestilence. There is a new model of war on a global stage, at the same time trying to limit nuclear deployment. The same problems that have historically derailed the progress of an equitable society have not gone away. With the development of antibiotics and vaccines, the contribution of infectious disease has been reduced, lifespan is increased for some, not all. There is shortened lifespan in impoverished societies and in wealthy societies associated with wasted human resources, greed and despair. Cancer is a disease of young and old, and it is organ specific, age specific, and linked to chronic disease with impaired T-cell immunity. The problem we are confronted with is that there is variability in the behavior of different cancers, some of which is related to transcription and suppression, and mutations. There was no knowledge of signaling pathways a century ago. Now mutation and mutagenesis in the course of the disease is a challenge to developing effective therapies, whether by chemo- or by immunological means. Single treatment modalities are the exception, not the rule.

The expression RAP physician refers to a group of physicians who the patient might not see – radiologists, anesthesiologists, and pathologists. Radiology has subspecialty in diagnostics and in radiotherapy. Anesthesiology is closely aligned with effective surgery. Cardiology also has developed an interventionist specialty that now rivals surgery. The pathologist has a crucial role in the diagnostic process that has continued to expand for decades. The only limitation it has is availability and skilled application of optical, genomic, proteomic, and lipidomic diagnostic methods.

If we put this matter aside, then we again have to think about when enough is enough. The prognosis of a cancer depends on the diagnosis or cancer type, the anaplasticity, the tumor size, migration to regional lymph nodes, and distant metastasis, which lends credence to staging, and add to that the matching of these elements with a personalized treatment. This last piece is in its infancy.

Chapter 3: A Diagnosis called “CANCER”

Chapter 4: Patients Experience with Invasive Surgery and Minimally Invasive Surgery

Chapter 5: Cancer Types – Patients Experience

Chapter 6: Contributing Factors to A Compromised Patient’s Wellbeing

Chapter 7: Metabolomics & Vitamins

Summary

Larry H. Bernstein, MD, FCAP

This chapter has covered a very large selection of cancers, the progression of different types, and the expected long term survivals. The topics of great concern are pharmacotherapy and immunotherapy, which is best when based on an extablished protocol, preferably personalized. This chapter also is concerned with what is now recognized as alternative medicine. This might be based on a chemical extraction from a plant therapy that has been known for centuries. This also refers to food-based supplements. This has created a large effort to develop neutraceuticals. This requires a much greater foundation in metabolic discovery than we have today.

Part Three

The Voice of Open Heart Surgery Survivors

Chapter 8: Cardiac Surgery

Volume Summary

Larry H. Bernstein, MD, FCAP

This volume of contributions has focused on the patient’s response to treatment, the expected response to pharmacotherapy, immunotherapy, and radiation therapy. The discussion also entails the difficulties in going beyond diagnosis to a grasp of long term survival. In examining the patient perspective, the patient and the physician have to be in concert with realistic expectations of toxicities, exacerbations, and the possibility of a decline into cachexia.

Epilogue

Larry H. Bernstein, MD, FCAP

Individual experiences with cancer, heart disease, and debilitation

I must conclude this volume with the observation that it is true in medicine and healthcare that the patient comes first. This calls for a respect for the patient’s best concerns. In the United States (USA), this might be an unusual statement given the great diversity we have as a people. Nevertheless, integration of communities takes time, economic disparities separate individuals and communities within communities, and there are religious and cultural values that divide one person from another. In this respect, families matter, and families may be divided.

There is a range of individual, social and chronic conditions that engage all of us. On the one hand there is the end-of-life experience. We grow old, but how do we grow old? In the case of cancer, we see that it inflicts pain and suffering at any age. The death of a child is experienced by the parents. Cancer requires some combination of surgery, postoperative chemo- or immunotherapy with local radiation. The chance of recurrence is not small, so the question is always when and how it will be reasserted.
The situation with heart disease is not quite the same. We might like to just be lost in the night, but we don’t have choices. We are also faced with combined chronic systemic conditions, and the heart, kidneys, brain, and lungs are fed by a vascular system. Consequently, it raises the likelihood of multisystem failure. In this situation the possibilities are unclear. The patient with end stage renal disease may go on dialysis in clinic or terminally at home.

The situation is most impressive at the patient end of the process. I still remember a woman of color who had experienced emotional distress and ended several marriages in divorce before she entered the “metropolitan” hospital in my medical school years and was found to have a sudden increase in blood pressure related to a rare adrenaline secreting adenoma of the Organ of Zuckerkandl. She had no visitors during her hospital experience. That was also a time when schizophrenia was not understood, and it also brought shame to a family.

Then there are myths to dispel. When a young woman got pregnant, it was a personal and a family crisis. This is still a situation today that has been highlighted by a juncture disclosed in a presidential contestant interview about whether an abortion, considered a moral issue by the church, is punishable. It also was stated that it would necessitate a return of “back-alley” abortions. It reminded me of the autopsy I performed as a resident on a woman who had pyelonephritis leading to end stage kidney disease. I am a triplet with a sister two years older than myself, and I only learned late in life that my mother had had an aborted pregnancy to alleviate the strain it would place on the family, my father earning a meager living. There is no easy way to conclude this than to say that to the patient, medicine is highly personal.

Volume One